Massachusetts Chapter of the American College of Surgeons

MCACS Home MCACS Home Past & Future Meetings Past & Future Meetings

Back to 2026 Display Posters


The Stablyx Arthroplasty System for Thumb CMC Arthritis: Comparative Outcomes Against Trapeziectomy
Jahnavi Challagonda1, Sivana Barron2, Megan Berube1, Jessica Farzan2, Jane McLarney2, Daniel Flynn1, Andrea Rhikkaella Buendia1, Janice Lalikos2, Anselm Wong2 1UMass Chan Medical School, Worcester, MA 2UMass Memorial Medical Center, Worcester, MA

Background: Carpometacarpal (CMC) joint arthritis affects up to 25% of women and 8.3% of men. Trapeziectomy remains the most common surgery for pain relief. The stablyx hemiarthroplasty system has limited long-term data. Methods: This IRB-approved retrospective cohort study included patients undergoing Stablyx and trapeziectomy between 2017 and 2025 at UMass Memorial Hospital. A total of 75 patients were included: 38 Stablyx patients and 37 trapeziectomy patients. Chart review collected demographic and outcomes data. Fisher’s exact tests and Wilcoxon tests were used. Results: Cohort averaged 60 years; 71% females. Stablyx patients had slightly lower PRWHE at first (75.7 vs 78.9, p = 0.18) and last visit (30.9 vs 36.8, p = 0.47). The minimal clinically important difference (MCID) in the change in PRWHE was similar for ≥15 (92.6% vs 85.0%, p = 0.64), but Stablyx trended higher in ≥ 20 (92.6% vs 75.0%, p = 0.12). In moderate-severe CMC arthritis, Stablyx had significantly more patients achieving MCID ≥ 20 (64.0% vs 34.4%, p = 0.035). Stablyx also showed generally higher ROM and fewer postoperative complications (16% vs 24%). Conclusion: Stablyx patients had slightly lower PRWHE scores at first and last visit, though not significant. In moderate to severe CMC arthritis, Stablyx had significantly more patients with MCID ≥ 20. Findings suggest Stablyx may improve outcomes in more severe cases, with higher ROM and fewer complications.
Back to 2026 Display Posters